Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Gore, M E Hariharan, S Porta, C Bracarda, S Hawkins, Robert E Bjarnason, G A Oudard, S Lee, S H Carteni, G Nieto, A
Gore, M E
Hariharan, S
Porta, C
Bracarda, S
Hawkins, Robert E
Bjarnason, G A
Oudard, S
Lee, S H
Carteni, G
Nieto, A
Citations
Altmetric:
Abstract
In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open-label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain metastases participating in this global EAP.
Description
Date
2011-02-01
Publisher
Collections
Keywords
Type
Article
Citation
Sunitinib in metastatic renal cell carcinoma patients with brain metastases. 2011, 117 (3):501-9 Cancer